These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32522525)

  • 21. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
    Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
    Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development.
    Heffeter P; Pape VFS; Enyedy ÉA; Keppler BK; Szakacs G; Kowol CR
    Antioxid Redox Signal; 2019 Mar; 30(8):1062-1082. PubMed ID: 29334758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-Met targeting in advanced gastric cancer: An open challenge.
    Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
    Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Met degradation: more than one stone to shoot a receptor down.
    Lefebvre J; Ancot F; Leroy C; Muharram G; Lemière A; Tulasne D
    FASEB J; 2012 Apr; 26(4):1387-99. PubMed ID: 22223753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
    Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
    Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cancer by binding iron: Dissecting cellular signaling pathways.
    Lui GY; Kovacevic Z; Richardson V; Merlot AM; Kalinowski DS; Richardson DR
    Oncotarget; 2015 Aug; 6(22):18748-79. PubMed ID: 26125440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
    Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
    Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in cancer therapy targeting c-Met signaling pathway.
    Jung KH; Park BH; Hong SS
    Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
    Cui JJ
    J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase.
    Merlot AM; Shafie NH; Yu Y; Richardson V; Jansson PJ; Sahni S; Lane DJR; Kovacevic Z; Kalinowski DS; Richardson DR
    Biochem Pharmacol; 2016 Jun; 109():27-47. PubMed ID: 27059255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
    Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
    PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.
    Stacy AE; Palanimuthu D; Bernhardt PV; Kalinowski DS; Jansson PJ; Richardson DR
    J Med Chem; 2016 Sep; 59(18):8601-20. PubMed ID: 27524608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
    Yap TA; Sandhu SK; Alam SM; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HGF-met signaling axis: emerging themes and targets of inhibition.
    Steffan JJ; Coleman DT; Cardelli JA
    Curr Protein Pept Sci; 2011 Feb; 12(1):12-22. PubMed ID: 21190524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current state of molecularly targeted drugs targeting HGF/Met.
    Yano S; Nakagawa T
    Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting MET: why, where and how?
    Ghiso E; Giordano S
    Curr Opin Pharmacol; 2013 Aug; 13(4):511-8. PubMed ID: 23797036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
    de Siqueira LRP; de Moraes Gomes PAT; de Lima Ferreira LP; de Melo Rêgo MJB; Leite ACL
    Eur J Med Chem; 2019 May; 170():237-260. PubMed ID: 30904782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired Resistance to a MET Antibody
    Pollmann SE; Calvert VS; Rao S; Boca SM; Madhavan S; Horak ID; Kjaer A; Petricoin EF; Kragh M; Poulsen TT
    Mol Cancer Ther; 2018 Jun; 17(6):1259-1270. PubMed ID: 29545332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
    Serda M; Kalinowski DS; Mrozek-Wilczkiewicz A; Musiol R; Szurko A; Ratuszna A; Pantarat N; Kovacevic Z; Merlot AM; Richardson DR; Polanski J
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5527-31. PubMed ID: 22858101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of clinic trials: agents targeting c-Met.
    Abidoye O; Murukurthy N; Salgia R
    Rev Recent Clin Trials; 2007 May; 2(2):143-7. PubMed ID: 18473999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.